PREVIOUS QUESTION:

 

NEXT QUESTION:

 

Is cabazitaxel (Jevtana) safe to use for prostate cancer?

ANSWER

The safety of cabazitaxel (Jevtana) and its effectiveness were established in a single, 755-patient study. All study participants had previously received docetaxel (Taxotere). The study was designed to measure overall survival (the length of time before death) in men who received cabazitaxel (Jevtana) in combination with prednisone as compared to those who received the chemotherapy drug mitoxantrone in combination with prednisone. The median overall survival for patients receiving the cabazitaxel (Jevtana) was 15.1 months compared with 12.7 months for those who received the mitoxantrone regimen.

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

NEXT QUESTION:

What are the side effects of using cabazitaxel (Jevtana) for prostate cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: